01Approach to the Critical Patient/attcp40

Acute digital ischemic crisis

›Ischemic crisis recognition

›Persistent digital pallor or cyanosis >30 minutes despite rewarming

›Immediate vasodilator therapy indicated

›IV prostanoid infusion if oral agents fail

›Digital gangrene or threatened tissue loss

›Urgent vascular surgery consultation

›Antiplatelet therapy with aspirin

›Pain uncontrolled with oral vasodilators

›Parenteral analgesia and vasodilation

›Hospital admission required

Initial stabilization

›Immediate rewarming protocol

›Remove patient from cold environment

›Warm room temperature target

›Blankets to body and extremities

›Warm water immersion of affected digits

›Temperature 38–40 degrees C

›Duration 15–20 minutes

›Avoid direct heat sources

›Burns risk in ischemic digits

›Heating pads contraindicated on ischemic tissue

Escalation triggers

›Criteria for urgent escalation

›Acute limb ischemia pattern

›Embolic or thrombotic cause must be excluded

›Vascular surgery emergent consult

›Signs of underlying systemic disease crisis

02History/hx130

Episode characterization

›Classic triphasic color change

›White (pallor): vasospasm phase

›Well-demarcated pallor of digits

›Onset with cold or stress trigger

›Blue (cyanosis): deoxygenation phase

›Cyanotic discoloration of affected digits

›May occur without preceding pallor in some patients

›Red (rubor): reperfusion phase

›Erythema and throbbing pain on rewarming

›Stinging sensation with blood return

›At least biphasic change (white and blue) required for diagnosis

›Uniphasic cold hands do not meet diagnostic criteria

›Diagnosis requires episodic, reversible, demarcated color change

Triggers and timing

›Precipitating factors

›Cold exposure in >80% of attacks

›Environmental cold (outdoors, cold air conditioning)

›Localized cold (cold objects, cold water)

›Emotional stress

›Sympathetic nervous system activation

›Can occur without temperature change

›Rapid temperature transitions

›Entering air-conditioned spaces

›Handling frozen foods

›Episode duration and frequency

›Typical attack duration 15–20 minutes after rewarming

›Prolonged attacks suggest secondary RP or ischemic crisis

›Seasonal pattern common (worse in winter)

›Frequency and progression over time

›Increasing frequency may indicate evolution to secondary RP

›Functional impairment assessment

Digit involvement pattern

›Anatomical distribution

›Fingers most commonly affected

›Thumb generally spared in primary RP

›Index, middle, ring fingers most common

›Toe involvement

›Foot vasospasm in more severe disease

›Bilateral symmetric pattern favors primary RP

›Asymmetric or single-digit involvement

›Raises concern for embolic or structural cause

›Requires vascular imaging

Associated symptoms

›Ischemic complications

›Digital ulcers or pitting scars

›Strongly suggests secondary RP

›Most common on fingertips

›Gangrene

›Rare; almost exclusively secondary RP

›Requires urgent management

›Sensory symptoms during attack

›Numbness and tingling

›Neural ischemia during vasospasm

›Resolves with reperfusion

›Pain

›Aching during pallor/cyanosis phase

›Throbbing during rubor phase

Connective tissue disease screen

›Musculoskeletal symptoms

›Arthralgia or arthritis

›Rheumatoid arthritis, SLE, Sjögren association

›Distribution pattern and morning stiffness

›Myalgia or muscle weakness

›Dermatomyositis or polymyositis association

›Proximal vs distal pattern

›Dermatologic symptoms

›Skin tightening or thickening

›Sclerodactyly suggests systemic sclerosis

›Proximal vs distal skin involvement

›Telangiectasias

›CREST syndrome feature

›Perioral telangiectasias in SSc

›Calcinosis cutis

›Calcium deposits under skin

›Painful and prone to ulceration

›Gastrointestinal symptoms

›Dysphagia

›Esophageal dysmotility in systemic sclerosis

›Early manifestation of SSc in some patients

›Gastroesophageal reflux

›Lower esophageal sphincter dysfunction in SSc

›Bloating and early satiety

›Pulmonary symptoms

›Dyspnea on exertion

›Interstitial lung disease in SSc or myositis

›Pulmonary arterial hypertension

›Dry cough

›ILD manifestation

›Sjögren airway involvement

›Sicca symptoms

›Dry eyes and dry mouth

›Sjögren syndrome primary association

›Secondary Sjögren overlap with SSc and SLE

Age of onset and demographics

›Onset age and type correlation

›Primary RP onset typically age 15–30 years

›Young female predominance

›No associated disease features

›Secondary RP onset typically >30–40 years

›New onset >40 years warrants secondary cause workup

›Consider malignancy (paraneoplastic) if B symptoms present

Medication and substance history

›Medications triggering or worsening RP

›Cardiovascular agents

›Beta-blockers (nonselective > selective)

›Clonidine

›Ergot-based and vasoconstrictor agents

›Ergot alkaloids and triptans

›Sympathomimetics and amphetamines

›Chemotherapeutic agents

›Bleomycin, cisplatin, vinblastine

›Especially for secondary occupational RP

›OTC decongestants and stimulants

›Pseudoephedrine, phenylephrine

›Caffeine (limited evidence)

›Recreational substances

›Cocaine

›Intense vasoconstriction

›Can precipitate digital ischemia

›Smoking status

›Critical to determine; worsens vascular disease

›Cessation is a first-line intervention

Occupational and family history

›Occupational exposures

›Vibratory tool use

›Hand-arm vibration syndrome (HAVS)

›Jackhammers, chainsaws, grinders

›Cold workplace exposure

›Meat processing, refrigeration workers

›Repetitive hand trauma

›Family history

›30–50% of primary RP patients have first-degree relative with condition

›Genetic susceptibility confirmed

›Autosomal dominant pattern suspected

›Family history of autoimmune disease

›Scleroderma, SLE, Sjögren, RA

›Increases secondary RP risk

03Physical Exam/exam94

Vital signs and general

›Stability assessment

›Blood pressure in both arms

›Asymmetry >20 mmHg systolic suggests large vessel disease

›Hypertension in scleroderma renal crisis

›Heart rate

›Tachycardia with sympathetic activation

›Arrhythmia in SSc cardiac involvement

›Oxygen saturation

›Baseline for pulmonary disease assessment

›Reduced in ILD or pulmonary hypertension

›General appearance

›Body habitus and nutritional status

›Cachexia in advanced CTD

›Cushingoid features if on steroids

Digital and vascular exam

›Digital examination

›Color of digits at presentation

›Active attack: pallor, cyanosis, or rubor

›Normal appearance between attacks is typical in primary RP

›Digital ulcers or pitting scars

›Pulp of fingertips most common location

›Highly specific for secondary RP

›Gangrene or necrosis

›Dry gangrene in chronic severe disease

›Wet gangrene if secondary infection

›Nail changes

›Pterygium inversum unguis in SSc

›Periungual telangiectasias

›Nailfold capillaroscopy

›Abnormal capillary pattern

›Giant capillary loops: early scleroderma pattern

›Capillary drop-out: active/late scleroderma pattern

›Sensitivity for SSc ~95%; highly specific

›Normal nailfold pattern favors primary RP

›Regular capillary distribution

›No megacapillaries or avascular areas

›Peripheral pulses

›Radial and ulnar pulses

›Diminished or absent suggests large vessel disease

›Allen test for palmar arch patency

›Brachial and femoral pulses

›Assess for proximal vascular disease

›Bruits suggest atherosclerotic disease

Skin and connective tissue exam

›Skin changes

›Sclerodactyly

›Tight, thickened skin of fingers

›Inability to flatten fingers on table (prayer sign)

›Skin thickening distribution

›Limited cutaneous SSc: distal to elbows and knees

›Diffuse cutaneous SSc: proximal involvement

›Telangiectasias

›Perioral or lip telangiectasias

›Palmar telangiectasias

›Calcinosis

›Calcium deposits over bony prominences

›Elbows, fingertips, knees

›Rash assessment

›Malar rash

›Butterfly distribution sparing nasolabial folds: SLE

›Photosensitive distribution

›Heliotrope rash and Gottron papules

›Dermatomyositis signature findings

›Purple periorbital discoloration

Musculoskeletal exam

›Joint assessment

›Synovitis

›Warmth, swelling, tenderness of small joints

›RA or SLE joint pattern

›Contractures

›Flexion contractures of fingers in SSc

›Functional assessment of grip

›Muscle assessment

›Proximal muscle strength

›Hip flexors, shoulder abductors

›Dermatomyositis/polymyositis pattern

Cardiopulmonary exam

›Pulmonary auscultation

›Bibasilar crackles

›ILD in SSc or myositis

›Velcro crackles characteristic of fibrosis

›Elevated jugular venous pressure

›Right heart failure from pulmonary hypertension

›Loud P2 on auscultation

›Cardiac exam

›Right ventricular heave

›Pulmonary arterial hypertension

›Tricuspid regurgitation murmur

PITFALLS

›Common examination errors

›Missing nailfold capillaroscopy

›Simple bedside tool with high diagnostic value

›Requires ophthalmoscope or dermatoscope

›Diagnosing acrocyanosis as RP

›Acrocyanosis is persistent, not episodic

›No pallor phase; no triphasic color change

›Overlooking asymmetric pulse findings

›Unilateral absence suggests structural/embolic cause

›Requires urgent vascular imaging

04Differential Diagnosis/ddx82

Primary vs secondary distinction

›Primary Raynaud's phenomenon (ICD-10: I73.00)

›Idiopathic vasospasm; no underlying disease

›Young female onset age 15–30 years

›Symmetric, episodic, reversible attacks

›Normal nailfold capillaroscopy

›Normal ANA and disease-specific antibodies

›No digital ulcers, tissue loss, or scarring

›Secondary Raynaud's phenomenon (ICD-10: I73.01)

›Associated with underlying systemic disease

›>90% of systemic sclerosis patients have RP

›Onset typically >30–40 years, more severe attacks

›Asymmetric involvement possible

›Digital ulcers and pitting scars common

›Abnormal nailfold capillaroscopy

Connective tissue disease associations

›Systemic sclerosis (ICD-10: M34.9)

›Most common secondary association

›RP may precede other SSc features by years

›Anticentromere antibodies (limited SSc) or anti-Scl-70 (diffuse SSc)

›Systemic lupus erythematosus (ICD-10: M32.9)

›RP in 10–45% of SLE patients

›Anti-dsDNA, anti-Sm antibodies

›Malar rash, serositis, nephritis

›Sjögren syndrome (ICD-10: M35.0)

›RP common in primary and secondary Sjögren

›Anti-SSA/Ro and anti-SSB/La antibodies

›Sicca symptoms dominant feature

›Rheumatoid arthritis (ICD-10: M06.9)

›RP in approximately 10% of RA patients

›RF and anti-CCP antibodies

›Symmetric joint disease

›Mixed connective tissue disease (ICD-10: M35.1)

›RP is hallmark feature

›High-titer anti-U1-RNP antibodies

›Overlap features of SSc, SLE, and myositis

Vascular and structural mimics

›Acrocyanosis (ICD-10: I73.8)

›Persistent symmetric cyanosis of hands and feet

›No pallor phase or triphasic change

›Benign; no treatment required

›Pernio (chilblains) (ICD-10: T69.1)

›Inflammatory lesions after cold/damp exposure

›Erythematous or violaceous papules/nodules

›Not episodic vasospasm

›Peripheral arterial disease (ICD-10: I73.9)

›Diminished or absent pulses

›Older patients with atherosclerotic risk factors

›Claudication rather than episodic color change

›Thoracic outlet syndrome (ICD-10: G54.0)

›Positional symptoms with arm elevation

›Unilateral, provoked by specific maneuvers

›Adson test positive

›Embolic digital ischemia

›Acute unilateral digital ischemia

›Cardiac source (atrial fibrillation, endocarditis)

›Proximal arterial aneurysm or ulcerated plaque

Hematologic causes

›Cryoglobulinemia (ICD-10: D89.1)

›Cold-induced immune complex precipitation

›Palpable purpura, neuropathy, glomerulonephritis

›Hepatitis C most common underlying cause

›Cold agglutinin disease (ICD-10: D59.1)

›IgM antibodies causing cold-induced hemolysis

›Livedo reticularis, acrocyanosis, anemia

›Positive cold agglutinin titer

›Polycythemia vera (ICD-10: D45)

›Hyperviscosity from elevated red cell mass

›Erythromelalgia overlap possible

›JAK2 V617F mutation

Other mimics

›Erythromelalgia (ICD-10: I73.81)

›Opposite of RP: burning pain, erythema, and warmth

›Triggered by heat and exercise

›Episodic; may coexist with RP in some patients

›Carpal tunnel syndrome (ICD-10: G56.0)

›Numbness and tingling in median nerve distribution

›May coexist with RP or mimic sensory symptoms

›Phalen and Tinel signs

›Achenbach syndrome

›Spontaneous venous hemorrhage of digits

›Self-limiting bruising of volar surface

›No vasospasm; often mistaken for RP

›Buerger disease (ICD-10: I73.1)

›Young male smokers with distal extremity ischemia

›Thromboangiitis obliterans

›Requires absolute smoking cessation

05Laboratory Tests/lt65

Initial workup for secondary RP screen

›Antinuclear antibody (ANA)

›Screening test for autoimmune CTD

›Positive in >90% of SSc patients

›Titer and pattern guide further testing

›Low titer ANA (1:40–1:80) common in primary RP; higher titers more specific

›Complete blood count

›Anemia of chronic disease in CTD

›Thrombocytopenia in SLE (immune-mediated)

›Elevated hematocrit in polycythemia vera

›Erythrocyte sedimentation rate and C-reactive protein

›Elevated in secondary RP and CTD

›Normal in primary RP

›Not specific; used for disease activity monitoring

›Comprehensive metabolic panel

›Renal function for SSc renal crisis

›Creatinine elevation with proteinuria

›Electrolytes in CTD management

Disease-specific autoantibodies

›Anticentromere antibodies

›Associated with limited cutaneous SSc (CREST)

›High specificity for SSc-limited cutaneous type

›Present in ~70% of limited SSc patients

›Anti-topoisomerase I (anti-Scl-70)

›Associated with diffuse cutaneous SSc

›Higher risk of ILD and digital ulcers

›Positive in ~30% of diffuse SSc patients

›Anti-dsDNA and anti-Sm

06Diagnostic Tests/dt83

Scoring Systems

›Raynaud's Condition Score (RCS)

›Patient-reported outcome measure for disease severity

›0–10 scale assessing functional impairment

›Validated for clinical trials in RP

›Used to track treatment response

›EULAR classification criteria for SSc (2013)

›Scoring system to classify systemic sclerosis

›Bilateral skin thickening of MCP joints: 9 points (sufficient alone)

›Raynaud's phenomenon: 3 points

›SSc-related antibodies: 3 points

›Score ≥9 classifies as SSc

›Modified Rodnan Skin Score (mRSS)

›Assesses skin thickness in SSc

›17 body areas; score 0–3 each (total 0–51)

›Used to track diffuse SSc progression

›Higher score correlates with organ involvement

›Allen and Brown diagnostic criteria for primary RP

›Episodic attacks triggered by cold or emotion

›Bilateral symmetric involvement

›Absence of tissue necrosis, gangrene, ulcers

›No underlying systemic disease

›Normal nailfold capillaries and negative ANA

MRI

›Cardiac MRI in SSc-associated RP

›Detection of cardiac Raynaud phenomenon

›Cold-induced myocardial perfusion defects demonstrable

›Reversible perfusion abnormalities with vasodilator challenge

›Left ventricular dysfunction induced by cold exposure in SSc patients

›Myocardial fibrosis assessment

›Late gadolinium enhancement pattern

›Patchy myocardial fibrosis typical in SSc cardiomyopathy

›MRI angiography of upper extremities

›Large vessel disease evaluation

›Indicated for suspected proximal vascular obstruction

›Subclavian or axillary artery occlusion

›Superior to CT for soft tissue and vessel wall detail

›MRI of hands

›Joint inflammation in CTD

›Synovitis, tenosynovitis, erosions in RA

›Soft tissue edema in early SSc

›Calcinosis detection (low signal nodules)

CT

›High-resolution CT chest (HRCT)

›Interstitial lung disease screening

›Mandatory in SSc patients with RP

›Non-specific interstitial pneumonia (NSIP) most common in SSc

›Ground-glass opacities and reticulation in lower lobes

›Honeycombing in advanced fibrosis

›Pulmonary arterial hypertension assessment

›Enlarged main pulmonary artery (>29 mm diameter)

›Right heart enlargement

›Mosaic attenuation pattern

›CT angiography of upper extremities

›Large vessel disease evaluation

›Thoracic outlet syndrome assessment

›Subclavian artery stenosis or aneurysm

›Dynamic imaging in provocative positions

Ultrasound

›Doppler ultrasound of upper extremity vessels

›Structural vascular disease evaluation

›Radial and ulnar artery flow assessment

›Detection of occlusive disease or aneurysm

›Duplex assessment before surgical sympathectomy

›Echocardiography

›Pulmonary arterial pressure estimation

›Tricuspid regurgitation jet velocity

›Right ventricular systolic pressure estimation

›Screening for PAH in SSc every 6–12 months recommended

›Left ventricular function in SSc cardiomyopathy

›Diastolic dysfunction common in SSc

›Pericardial effusion assessment

›Nailfold videocapillaroscopy (NVC)

›Gold standard for detecting microvascular damage

›Performed with dermatoscope or ophthalmoscope

›Three SSc patterns: early, active, late

›Early: giant capillaries, few hemorrhages, relatively preserved density

›Active: giant capillaries, capillary hemorrhages, moderate drop-out

›Late: absent/avascular areas, disorganized architecture

›Normal pattern favors primary RP

›Sensitivity for SSc approximately 95%

›Abnormal NVC is independent predictor of SSc evolution

›Cold stimulation test

›Provocation testing for RP

›Digital cooling followed by temperature recovery monitoring

›Prolonged recovery time >20 minutes supports RP diagnosis

›Not required for clinical diagnosis; used in research settings

07Disposition/dispo45

Discharge criteria

›Suitable for discharge

›Primary RP diagnosis established

›Symptoms resolved with rewarming

›No digital ulcers, gangrene, or tissue loss

›Reliable follow-up arranged

›PCP within 2–4 weeks if starting medication

›Rheumatology if secondary RP suspected

›Patient education completed

›Trigger avoidance counseled

›Lifestyle modification instructions provided

›Medication prescriptions and side effects reviewed

Admission criteria

›Indications for hospital admission

›Acute digital ischemic crisis

›Persistent ischemia not responding to oral vasodilators

›IV iloprost infusion required

›Digital gangrene or necrotic tissue

›Surgical or interventional management required

›IV antibiotics if secondary infection present

›New secondary RP with systemic emergency

›Scleroderma renal crisis: ACE inhibitor therapy urgently required

›Pulmonary hypertension decompensation

›Uncontrolled severe pain

›Requiring parenteral analgesia

Specialist referral indications

›Rheumatology referral

›Any positive autoantibody result

08Treatment/t117

Nonpharmacologic therapy (first-line for all patients)

›Cold avoidance strategies

›Layered clothing

›Gloves, hats, scarves for extremity protection

›Heated gloves or footwear for severe disease

›Chemical hand warmers as adjuncts

›Body temperature maintenance

›Core warming reduces sympathetic vasoconstriction

›Avoid direct contact with cold surfaces

›Home and workplace modifications

›Insulated beverage holders

›Oven mitts when accessing refrigerator

›Lifestyle modifications

›Smoking cessation

›Nicotine causes direct vasoconstriction

›Reduces digital blood flow and worsens outcomes

›Strongest modifiable risk factor

›Stress reduction

›Biofeedback therapy shown to reduce attack frequency

›Relaxation techniques for sympathetic activation

›Regular exercise

›Improves peripheral circulation

›Avoid exercising in cold environments

›Medication avoidance

›Discontinue or substitute offending medications

›Beta-blockers: switch to cardioselective or alternative

›Ergotamines: avoid in patients with RP

›Sympathomimetics including OTC decongestants

First-line pharmacotherapy

›Dihydropyridine calcium channel blockers

›Nifedipine sustained-release

›Starting dose 30 mg/day orally

›Titrate up to 60–90 mg/day based on response and tolerability

›Cochrane review: approximately 1.7 fewer attacks/week vs placebo

›Class I recommendation for primary RP

›Amlodipine

›Starting dose 5 mg/day orally

›Titrate to 10 mg/day if tolerated

›Longer half-life; once daily dosing advantage

›Comparable efficacy to nifedipine in trials

›Common side effects of CCBs

›Headache (dose-dependent)

›Peripheral edema (ankle swelling)

›Flushing and hypotension

›Reflex tachycardia with immediate-release nifedipine

Second-line pharmacotherapy

›Phosphodiesterase-5 inhibitors

›Sildenafil

›20 mg three times daily orally

›Especially effective for digital ulcers and secondary RP

›Inhibits PDE-5, increasing cGMP and causing vasodilation

›Contraindicated with nitrates (severe hypotension risk)

›Tadalafil

›5–20 mg/day orally

›Longer duration of action than sildenafil

›Once-daily dosing option

›Topical nitroglycerin

›2% nitroglycerin ointment

›One-quarter to one-half inch applied to affected digits daily

›Local vasodilation with reduced systemic side effects

›Headache common even with topical application

›Do not combine with oral PDE-5 inhibitors

›Angiotensin receptor blockers

›Losartan

›50 mg/day orally

›RCT evidence for reduction in frequency and severity

›Alternative for patients intolerant to CCBs

›Renal function monitoring required

›Selective serotonin reuptake inhibitors

›Fluoxetine

›20 mg/day orally

›Open-label data suggest efficacy

›Mechanism: reduces platelet serotonin-mediated vasoconstriction

›Option for patients with comorbid depression

›Alpha-1 blockers

›Prazosin

›1–5 mg orally two to three times daily

›Blocks sympathetic vasoconstriction

›First-dose hypotension: initiate at bedtime

›Limited to patients not responding to CCBs or PDE-5 inhibitors

Severe or refractory disease

›IV iloprost (prostacyclin analogue)

›Indications

›Acute digital ischemic crisis refractory to oral therapy

›Severe secondary RP with critical digital ischemia

›Digital ulcers requiring urgent healing support

›Dosing protocol

›0.5–2 nanograms/kg/minute IV infusion

›Titrated over 6 hours daily for 3–5 days

›Requires hospital-based administration and monitoring

›Reduces attack frequency up to 10 weeks after treatment

›Bosentan (endothelin receptor antagonist)

›Indications and dosing

›Reduces new digital ulcer formation in systemic sclerosis

›Starting dose 62.5 mg orally twice daily for 4 weeks

›Maintenance dose 125 mg orally twice daily

›Not indicated for healing existing ulcers; prevents new ones

›Monitoring requirements

›Liver function tests monthly (hepatotoxicity risk)

›Teratogenic: contraception mandatory in women of childbearing age

›Monthly pregnancy tests required

›Botulinum toxin A injections

›Emerging evidence for refractory RP

›Injection into palmar digital vessels

›Inhibits sympathetic nerve-mediated vasoconstriction

›Reduction in attack frequency and severity reported

›Limited by procedure availability and cost

›Aspirin during acute ischemic crisis

›325 mg orally or IV

›Antiplatelet effect in critical digital ischemia

›Adjunct to vasodilator therapy

›Continue until ischemia resolved

Surgical options

›Digital sympathectomy

›Indications

›Refractory critical digital ischemia with threatened limb

›Failed maximal medical therapy

›Vascular surgery referral required

›Technique

›Periadventitial stripping of digital arteries

›Local procedure with high short-term success

›Effect may wane after 1–2 years

09Special Populations/sp80

Pregnancy

›RP in pregnancy considerations

›Physiologic changes affecting RP

›Increased plasma volume and cardiac output may reduce attack frequency

›Elevated estrogen levels may have vasodilatory effect

›Many patients improve during pregnancy

›Medication safety

›Nifedipine: Category C; used for preterm labor; generally considered acceptable

›Amlodipine: limited human data; use only if benefit outweighs risk

›Sildenafil: studied in pulmonary hypertension in pregnancy; use with caution

›Medications to avoid in pregnancy

›Bosentan: teratogenic (Category X); absolutely contraindicated

›Losartan: contraindicated in second and third trimester (fetotoxicity)

›IV iloprost: data insufficient; use only in life-threatening ischemia

›Nonpharmacologic emphasis

›Cold avoidance and protective clothing preferred

›Smoking cessation paramount

›Stress reduction techniques safe and effective

›Secondary RP in pregnancy (SSc, SLE)

›SSc pregnancy complications

›Scleroderma renal crisis risk in early diffuse SSc

›ACE inhibitors required for renal crisis even in pregnancy (exception to general rule)

›Pulmonary hypertension: high maternal mortality; specialist co-management essential

›SLE pregnancy management

›Hydroxychloroquine continued through pregnancy (reduces lupus flares)

›Neonatal lupus risk with anti-SSA/Ro antibodies

›Antiphospholipid syndrome: low-dose aspirin and heparin

Geriatric

›RP in older adults

›Age-related vascular changes

›Increased arterial stiffness reduces vasomotor reserve

›Attenuated autonomic responses affect vasoconstriction magnitude

›New RP onset in elderly warrants aggressive secondary cause search

›Polypharmacy considerations

›Review all medications for vasoconstrictive agents

›Beta-blockers: common in elderly for cardiovascular disease; consider alternatives

›Ergotamines for headache: identify and substitute

›CCB therapy in older adults

›Higher risk of peripheral edema with nifedipine

›Hypotension risk greater; start at lowest dose

›Amlodipine preferred for better tolerability in elderly

›Fall risk with vasodilators

›Orthostatic hypotension from CCBs and alpha-blockers

›Prazosin first-dose effect particularly hazardous in elderly

›Supine blood pressure monitoring recommended

›Secondary RP workup in elderly

›Malignancy-associated RP

›Paraneoplastic RP possible with late onset

›B symptoms (fever, weight loss, night sweats) prompt cancer screen

›CT chest/abdomen/pelvis for malignancy evaluation

›Atherosclerotic disease overlap

›PAD commonly coexists in elderly

›Ankle-brachial index to exclude PAD

›Statin and antiplatelet therapy for PAD overlap

Pediatrics

›Pediatric RP characteristics

›Rarity in children

›New onset in childhood should prompt secondary cause evaluation

›True primary RP can occur but is uncommon

›Mean age of presentation in secondary pediatric RP: 8–11 years

›Pediatric secondary RP associations

›Juvenile idiopathic arthritis

›Juvenile SLE (jSLE)

›Mixed connective tissue disease

›Hypothyroidism in children

›Medication dosing in children

›Nifedipine in pediatrics

›0.25–0.5 mg/kg/day orally divided every 8–12 hours

›Maximum 3 mg/kg/day or adult dose (whichever lower)

›Extended-release formulations preferred for compliance

›Amlodipine in pediatrics

›0.05–0.1 mg/kg/day orally once daily

›Maximum 5 mg/day in children aged 6–17 years

›Lower risk of headache than nifedipine

›PDE-5 inhibitors in pediatrics

›Sildenafil approved for pediatric pulmonary hypertension

›Off-label use for secondary RP in children

›Dose adjustment required by weight

›Nonpharmacologic in children

›Environmental modifications at home and school

›Locker insulation, gloves for outdoor activities

›Avoidance of air-conditioned environments when possible

›Parental education about trigger avoidance

10Background/b90

Epidemiology

›Prevalence

›Affects 3–5% of the general population

›Wide geographic variation (higher in cold climates)

›Prevalence in women 2–20%; in men 1–12%

›Female predominance

›F:M ratio approximately 4:1

›Hormonal and genetic factors contribute

›Primary vs secondary distribution

›Primary RP: 80–90% of cases

›Secondary RP: 10–20% of cases

›Secondary RP more common in older patients and those with CTD

›Associated disease prevalence

›Systemic sclerosis

›>90% of SSc patients have RP

›RP may precede other SSc manifestations by years

›SLE: RP in 10–45% of patients

›Sjögren syndrome: RP in approximately 30–40%

›Rheumatoid arthritis: RP in approximately 10%

›Risk factors

›Female sex

›Cold climate and seasonal variation

›Family history (30–50% of primary RP have affected first-degree relative)

›Occupational vibration exposure (HAVS)

›Smoking

›Positive ANA or disease-specific autoantibodies

›Cardiovascular risk

›Recent data: RP associated with increased cardiovascular disease and VTE risk

›Independent of traditional cardiovascular risk factors

›2025 data: higher rates of MI, stroke, and VTE compared to controls

Pathophysiology

›Vascular mechanism

›Exaggerated vasospastic response to cold or emotional stress

›Abnormal alpha-2 adrenoceptor sensitivity in digital vessels

›Increased endothelin-1 production causing vasoconstriction

›Reduced nitric oxide bioavailability from endothelial dysfunction

›Platelet and coagulation dysregulation

›Platelet activation and thromboxane A2 release during attacks

›Increased serotonin release contributes to vasoconstriction

›Fibrinolytic abnormalities in secondary RP

›Primary RP mechanism

›Functional vasospasm without structural vascular disease

›Normal nailfold capillary architecture

›No evidence of inflammation or intimal fibrosis

›Reversible episodes with complete recovery

›Secondary RP mechanism (SSc model)

›Structural vascular disease with superimposed vasospasm

›Intimal fibrosis and luminal narrowing of digital arteries

›Perivascular fibrosis from collagen deposition

›Endothelial activation with ICAM-1 and VCAM-1 upregulation

›Microvascular damage progression

›Loss of capillary density (capillary drop-out)

›Giant capillary loops from compensatory angiogenesis

›Progressive digital ischemia leading to ulcers and tissue loss

›Triphasic color change pathophysiology

›White phase: intense vasospasm causing complete blood flow cessation

›Complete digital blanching

›Triggered by cold or sympathetic activation

›Blue phase: deoxygenation of residual blood in static capillaries

›Cyanotic discoloration from deoxyhemoglobin

›May be absent in some patients

›Red phase: reactive hyperemia on reperfusion

›Vasodilation with rapid blood return

›Throbbing pain and erythema

Therapeutic Considerations

›Primary RP treatment principles

›Majority managed nonpharmacologically

›Cold avoidance and protective clothing sufficient in mild disease

›Pharmacotherapy for moderate-severe disease or functional impairment

›CCBs evidence base

›Cochrane 2021 review (Vasodilators for Primary RP)

›Nifedipine: approximately 1.7 fewer attacks/week vs placebo

›Amlodipine: comparable efficacy with better tolerability

›ACEP/rheumatology guidelines: first-line pharmacotherapy

›Secondary RP treatment principles

›Target underlying disease in parallel with symptomatic RP therapy

›Immunosuppression for active CTD

›Organ-specific therapy (pulmonary vasodilators for PAH)

›Digital ulcer prevention and healing

›PDE-5 inhibitors preferred for digital ulcer healing

›Bosentan for prevention of new ulcers in SSc

›IV iloprost for acute crisis and refractory ulcers

›Antiplatelet therapy

›Low-dose aspirin during acute ischemic crisis

›Routine antiplatelet therapy not established for RP generally

›Monitoring and treatment escalation

›Primary RP annual reassessment

›Evolving autoimmune features (15–20% with ANA/abnormal capillaroscopy develop CTD in 2 years)

›Serial nailfold capillaroscopy not routine but informative

›Secondary RP surveillance

›Echocardiography annually for PAH screening in SSc

›HRCT chest in SSc patients at baseline and with symptoms

›Pulmonary function tests with DLCO annually in SSc

11Patient Discharge Instructions/pdi44

copy discharge instructions

›What is Raynaud's phenomenon?

›Raynaud's is a condition where blood vessels in your fingers (and sometimes toes) overreact to cold or stress, causing temporary color changes

›Your fingers may turn white (blood flow stops), then blue (low oxygen), then red (blood returns)

›Attacks usually last 15–20 minutes and resolve with warming

›It is a chronic condition that can be managed with lifestyle changes and medications

›Avoid your triggers

›Cold exposure is the main trigger

›Wear gloves and warm clothing outdoors

›Avoid holding cold drinks or frozen foods with bare hands

›Use insulated cups and oven mitts when cooking

›Emotional stress can trigger attacks

›Practice relaxation techniques and stress management

›If you have significant anxiety, discuss treatment with your doctor

›Medications that worsen Raynaud's

›Do not start new medications (including cold/allergy medicines) without telling your doctor

›Some common medicines like beta-blockers and nasal decongestants can trigger attacks

›Your medications

›Nifedipine or amlodipine (if prescribed)

›Take as directed every day; do not skip doses

›Common side effects: headache, ankle swelling, flushing

›These side effects often improve over time

›Do not use sildenafil (Viagra) type medications if you use nitrate sprays (serious low blood pressure risk)

›Always tell your doctor all medications you take

›Lifestyle changes

›Stop smoking immediately

›Smoking severely worsens blood flow to your fingers

›Ask your doctor for help with smoking cessation

12References/r41

Guidelines and key sources

›Wigley FM, Flavahan NA — Raynaud's Phenomenon

›New England Journal of Medicine, 2016

›Comprehensive review of pathophysiology, diagnosis, and management

›Primary reference for diagnostic criteria and stepwise treatment

›Su KY, Sharma M, Kim HJ, et al — Vasodilators for Primary Raynaud's Phenomenon

›Cochrane Database of Systematic Reviews, 2021

›Nifedipine reduces attack frequency by approximately 1.7 attacks/week vs placebo

›Supports CCBs as first-line pharmacotherapy

›Rirash F, Tingey PC, Harding SE, et al — Calcium Channel Blockers for Primary and Secondary Raynaud's Phenomenon

›Cochrane Database of Systematic Reviews, 2017

›Confirms efficacy of CCBs across primary and secondary RP

›Ennis H, Hughes M, Anderson ME, Wilkinson J, Herrick AL — Calcium Channel Blockers for Primary Raynaud's Phenomenon

›Cochrane Database of Systematic Reviews, 2016

›Nifedipine evidence base; tolerability data

›Klein-Weigel P, Sander O, Reinhold S, et al — Raynaud's Phenomenon: A Vascular Acrosyndrome That Requires Long-Term Care

›Deutsches Arzteblatt International, 2021

›Long-term management and monitoring recommendations

›Haque A, Hughes M — Raynaud's Phenomenon

›Clinical Medicine, 2020

›Clinical review including risk stratification and treatment algorithm

›Pauling JD, Hughes M, Pope JE — Raynaud's Phenomenon — An Update on Diagnosis, Classification and Management

›Clinical Rheumatology, 2019

›Updated classification and management framework

›Ramahi A, Hughes M, Khanna D — Practical Management of Raynaud's Phenomenon

›Current Opinion in Rheumatology, 2022

›Practical clinical approach for practicing physicians

›Di Donato S, Huang S, Pauling JD, et al — Clinically Relevant Differences Between Primary RP and Secondary to CTD

Evidence & Review